Merck, Inc.
🇺🇸United States
MK0457 in Patients With Leukemia (0457-003)
Phase 1
Completed
- Conditions
- Lymphocytic Leukemia, B Cell, AcuteChronic Myelogenous Leukemia in Blast CrisisMyelodysplastic SyndromesMyelogenous Leukemia, Chronic
- Interventions
- First Posted Date
- 2005-05-25
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT00111683
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
- First Posted Date
- 2005-05-05
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 39
- Registration Number
- NCT00110188
- Locations
- 🇺🇸
Louis Warchaw Prostate Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Wisconsin, Madison, WI, Madison, Wisconsin, United States
🇺🇸Beth Israel Deaconess Medical Center/MGH/DFCI, Boston, Massachusetts, United States
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
Phase 3
Terminated
- Conditions
- MyelodysplasiaMyelomonocyticLeukemia, Myelomonocytic, ChronicMyelodysplastic Syndromes
- Interventions
- Other: Placebo
- First Posted Date
- 2005-04-29
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT00109538
V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
Phase 3
Completed
- Conditions
- MeaslesMumpsVaricellaRubella
- First Posted Date
- 2005-04-27
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1027
- Registration Number
- NCT00109343
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
Phase 2
Completed
- Conditions
- Measles
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1100
- Registration Number
- NCT00109278
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
Phase 2
Completed
- Conditions
- Shingles
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 180
- Registration Number
- NCT00109122
A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)
Phase 2
Completed
- Conditions
- Smoking
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT00109135
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
Phase 1
Terminated
- Conditions
- Multiple Myeloma
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00109109
An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)
Phase 2
Completed
- Conditions
- Obesity
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 500
- Registration Number
- NCT00109148
Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)
Phase 3
Completed
- Conditions
- Ocular HypertensionGlaucoma
- First Posted Date
- 2005-04-13
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 330
- Registration Number
- NCT00108017
© Copyright 2025. All Rights Reserved by MedPath